Who
Mark Hollywood
EVP & Chief Operating Officer
Company insider
Files Form 4 as: EVP & Chief Operating Officer, Zymeworks.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $278K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Jan 2026
- Last trade
- 6 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 6 Jul 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code A | $21K939 at $22.22 | filing |
| 6 Jul 2026filed 6 Jul 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code A | $21K939 at $22.22 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $139K6,120 at $22.67 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $139K6,120 at $22.67 | filing |
News
Zymeworks Names Suzanne Monahan to Lead YUPELRI Commercial StrategyZYME · econotimes.com · 19 Oct 2026Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaZYME · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Mark Hollywood; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.